Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy
K Wudhikarn, MA Perales - Bone marrow transplantation, 2022 - nature.com
CD19-targeted chimeric antigen receptor (CAR) T-cell becomes a breakthrough therapy
providing excellent remission rates and durable disease control for patients with …
providing excellent remission rates and durable disease control for patients with …
[HTML][HTML] Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow …
Background Several commercial and academic autologous chimeric antigen receptor T-cell
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …
Vaccine schedule recommendations and updates for patients with hematologic malignancy post‐hematopoietic cell transplant or CAR T‐cell therapy
G Reynolds, VG Hall, BW Teh - Transplant Infectious Disease, 2023 - Wiley Online Library
Revaccination after receipt of a hematopoietic cell transplant (HCT) or cellular therapies is a
pillar of patient supportive care, with the potential to reduce morbidity and mortality linked to …
pillar of patient supportive care, with the potential to reduce morbidity and mortality linked to …
Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients
X Wu, L Wang, L Shen, L He, K Tang - Journal of hematology & oncology, 2022 - Springer
Recipients after hematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor
T-cell (CAR-T) therapy are at increased risk for unfavorable outcomes after SARS-CoV-2 …
T-cell (CAR-T) therapy are at increased risk for unfavorable outcomes after SARS-CoV-2 …
Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients
Hematopoietic cell transplantation (HCT) and cellular therapy (CT) recipients have poor
outcomes after developing COVID-19 (Spanjaart et al., 2021, Meir et al., 2021). HCT and/or …
outcomes after developing COVID-19 (Spanjaart et al., 2021, Meir et al., 2021). HCT and/or …
Efficacy of SARS-CoV-2 primary and booster vaccine doses in CAR-T recipients–targeting the target antigen
Immunocompromised patients who develop COVID-19 infection have worse outcomes [1, 2].
Patients with hematological malignancies (HM) who receive hematopoietic cell …
Patients with hematological malignancies (HM) who receive hematopoietic cell …
Evidence of exhausted lymphocytes after the third anti-SARS-CoV-2 vaccine dose in cancer patients
JD Benitez Fuentes, K Mohamed Mohamed… - Frontiers in …, 2022 - frontiersin.org
Introduction Evidence is scant regarding the long-term humoral and cellular responses Q7
triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA …
triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA …
COVID‐19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)‐T‐cell therapy
More than 3 years have passed since Coronavirus disease 2019 (COVID‐19) was declared
a global pandemic, yet COVID‐19 still severely impacts immunocompromised individuals …
a global pandemic, yet COVID‐19 still severely impacts immunocompromised individuals …
Humoral and cellular responses to SARS-CoV-2 vaccines before and after chimeric antigen receptor–modified T-cell therapy
MA Gonzalez, AM Bhatti, K Fitzpatrick… - Blood …, 2023 - ashpublications.org
COI notes: JAH received consulting fees or honoraria from Gilead Sciences, Amplyx, Allovir,
Allogene therapeutics, CRISPR therapeutics, CSL Behring, OptumHealth, Octapharma, and …
Allogene therapeutics, CRISPR therapeutics, CSL Behring, OptumHealth, Octapharma, and …
[HTML][HTML] Severe acute respiratory syndrome coronavirus 2 vaccine immunogenicity among chimeric antigen receptor T cell therapy recipients
MM Aleissa, JS Little, S Davey, A Saucier… - … and cellular therapy, 2023 - Elsevier
Patients receiving chimeric antigen receptor T cell (CAR-T) therapy may have impaired
humoral responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
humoral responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …